Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Slower spending on biotech and pharma research and development has been a headwind to the stock, which gave an opportunity to invest at an attractive discount to estimated intrinsic value.
— Jonathan Edwards, Jonathan Mueller
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. ($CRL), representing 3.4% of the composite, provides early-stage contract research services, animal models, and clinical discovery support for global pharmaceutical and biotechnology corporations. Ariel maintains a...
Charles River Laboratories ($CRL) provides essential preclinical laboratory testing, animal models, and drug discovery research services to biotechnology and pharmaceutical firms, accounting for 4.6% of fund assets. The manager maintains...
Charles River Laboratories ($CRL), which represents 3.9% of the fund's portfolio, is an essential contract research organization providing discovery and safety assessment services, laboratory products, and manufacturing support to the global biopharmaceutical industry. The manager holds...